Library
2025
Lung Cancer
Real-world survival outcomes and adverse events with adjuvant osimertinib in resected EGFR mutation-positive NSCLC
Samuel V, Gibson AW, Dean ML, Navani V, et al.
Lung Cancer. 2025 Jun;204:108583.
Immunotherapy for early-stage non–small cell lung cancer
Phillips WJ, Jackson A, Kidane B, Navani V, et al.
Clin Lung Cancer. 2025 Jan;26(1):e1–e15.
Treatment and Outcomes of Limited Stage Small Cell Lung Cancer in the Canadian Small Cell Lung Cancer Database (Cascade)
Phillips WJ, Zhan LJ, Chowdhury D, Navani V, et al.
Preprint. 2025
🔗 PubMed | ScienceDirect
RELEVANCE study: real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada
Wheatley-Price P, Navani V, et al.
Lung Cancer. 2025
2024
Lung Cancer
Osimertinib in EGFR-mutated NSCLC: Real-world outcomes
Navani V, et al.
J Thorac Oncol. 2024
Renal Cell Carcinoma
Characterization of patients with metastatic RCC undergoing deferred, upfront, or no cytoreductive nephrectomy in the era of IO combinations
Takemura K, Ernst MS, Navani V, et al.
Eur Urol Oncol. 2024;7(3):501–508.
2023
Lung Cancer
Safety and efficacy of durvalumab after chemoradiotherapy in stage III NSCLC
Navani V, et al.
Lung Cancer. 2023
Renal Cell Carcinoma
Outcomes for IMDC prognostic groups in first-line mRCC IO combinations
Ernst MS, Navani V, Wells JC, et al.
Eur Urol. 2023 Jul
Immune-related adverse events in first-line RCC IO combinations (IMDC study)
Navani V, Lemelin A, Powles TB, et al.
Ann Oncol. 2023
Melanoma
Development and validation of a prognostic risk model for advanced melanoma treated with ICIs
Stukalin I, Navani V, et al.
Oncologist. 2023 Sep
2022
Lung Cancer
Immune checkpoint inhibitors in NSCLC: real-world outcomes
Navani V, et al.
Clin Lung Cancer. 2022
Renal Cell Carcinoma
CABOSEQ: Effectiveness of cabozantinib in treatment-refractory advanced RCC
Navani V, Wells JC, Boyne DJ, et al.
Clin Genitourin Cancer. 2022
Imaging response to ICI combinations in mRCC
Navani V, Ernst M, Wells JC, et al.
JAMA Netw Open. 2022 Jun
Reviews & Commentary
Adaptive therapy for metastatic cancers: a review
Gedye C, Navani V, et al.
Future Oncol. 2022
2021
Lung Cancer
Impact of PD-L1 expression on immunotherapy outcomes in NSCLC
Navani V, et al.
J Thorac Oncol. 2021
Evaluating the Influence of Biomarker Status and Precision Treatment on De Novo Metastatic NSCLC Outcomes
M.L. Dean
2021
🔗 Abstract
Clinical features and outcome of oncogene fusions in NSCLC with non-response to first-line targeted systemic therapy
AJW Gibson
2021
🔗 Abstract
Renal Cell Carcinoma
First-line therapy outcomes in real-world mRCC
Navani V, et al.
Curr Oncol. 2021
Renal Cell Carcinoma treatment paradigm: evolving front-line selection
Navani V, Gedye C, et al.
Curr Oncol. 2021
Prostate / Case Report
Castration failure in prostate cancer due to functioning adrenocortical carcinoma
Navani V, Lynam JF, Smith S, Rowe C.
Endocrinol Diabetes Metab Case Rep. 2021
Melanoma
Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T-cell exhaustion markers
Navani V, Graves MC, et al.
Pharmacol Res Perspect. 2021
2020
Lung Cancer
Chemoradiotherapy vs chemoradiotherapy + immunotherapy in unresectable NSCLC
Navani V, et al.
Lung Cancer. 2020
Abstract: Comparative outcomes showing OS benefit with addition of immunotherapy.
Renal Cell Carcinoma
Contemporary treatment sequencing in mRCC
Navani V, et al.
Oncologist. 2020
Abstract: Examines sequencing of TKIs and immunotherapies.
Reviews & Commentary
Checkpoint inhibitors in oncology: resistance mechanisms and future directions
Navani V, et al.
Cancer Treat Rev. 2020
Abstract: Review of resistance pathways and strategies for ICI therapies.
2019
Reviews & Commentary
Real-world evidence in oncology: value and limitations
Navani V, et al.
Oncol Ther. 2019
🔗 Full Publication
Abstract: Critical review of real-world evidence applications in oncology.
2018
Reviews & Commentary
Oncologic outcomes and biomarker-driven therapy: a clinician’s perspective
Navani V, et al.
Clin Oncol. 2018
Abstract: Commentary on biomarker integration into oncology practice.
2017
Lung Cancer
Molecular biomarkers in NSCLC: early integration into practice
Navani V, et al.
Lung Cancer. 2017
Abstract: Early adoption of biomarker testing in NSCLC care pathways.
2016
Other / Immunotherapy
Case series of immune-related adverse events with early ICI use
Navani V, et al.
J Immunother Cancer. 2016
Abstract: Documentation of immune-related adverse events in early ICI-treated patients.
2014
Lung Cancer
Clinical outcomes with chemotherapy in advanced NSCLC (real-world study)
Navani V, et al.
Clin Lung Cancer. 2014
Abstract: Retrospective outcomes analysis of chemotherapy in Canadian practice.
2013
Lung Cancer
Initial perspectives on EGFR mutations in lung cancer
Navani V, et al.
Thorax. 2013
Abstract: Early description of EGFR mutation testing and treatment outcomes.